- Adragos Pharma has signed a strategic agreement with Towa Pharmaceutical to supply up to 1.5 billion tablets annually.
- The partnership includes capacity expansion at the Kawagoe plant from 1.0 billion to 2.5 billion tablets per year.
Adragos Pharma has entered into a strategic collaboration agreement with Towa Pharmaceutical to support the stable supply of off-patent pharmaceuticals in Japan. Under the agreement, Adragos will provide contract manufacturing services from its Kawagoe plant, supplying up to 1.5 billion tablets annually to Towa on a planned basis.
The partnership is designed to address increasing demand for reliable domestic supply of off-patent medicines. Both companies will share demand and supply forecasts to support production planning and ensure consistent availability of products.
As part of the agreement, Adragos Pharma will accelerate capital investment at its Kawagoe facility to expand annual solid-dosage manufacturing capacity from 1.0 billion tablets to 2.5 billion tablets in stages. Approximately 1.5 billion tablets of this capacity will be allocated to Towa Pharmaceutical.
The collaboration reflects the role of CDMOs and contract manufacturing in strengthening pharmaceutical supply chains. Adragos stated that the investment will support production resilience, enhance quality assurance systems, and contribute to long-term supply stability in Japan.
“Through capital investment at our Kawagoe plant, we will further strengthen our production and quality assurance systems and, with quality as our highest priority, contribute to a more stable domestic supply of medicines.”
Masanori Kurogome, Representative Director of Adragos Pharma Kawagoe
